Awaiting product image

Philadelphia Chromosome / Bcr-Abl – Quantitative

₹6,000.00

15 minutes
Categories: ,

The Philadelphia Chromosome BCR-ABL – Quantitative Test measures the amount of BCR-ABL fusion gene in the blood or bone marrow. This gene is formed when parts of chromosome 9 and chromosome 22 break and reattach, creating an abnormal gene that leads to the production of a protein that can cause leukemia, particularly chronic myelogenous leukemia (CML).

Unlike the qualitative test, which simply detects the presence or absence of the BCR-ABL gene, this quantitative test measures the level of the gene’s expression, providing more detailed information about the disease’s progression and response to treatment.

Description

Why It’s Done
The BCR-ABL Quantitative Test is typically used to:
• Diagnose chronic myelogenous leukemia (CML) and monitor its progression.
• Assess treatment effectiveness in patients undergoing therapy for CML, especially those on tyrosine kinase inhibitors (TKIs).
• Monitor minimal residual disease (MRD), which refers to the small number of leukemia cells that may remain after treatment and are often undetectable by other tests.
• Predict relapse risk: A rising level of BCR-ABL may indicate that the leukemia is returning, even if symptoms haven’t appeared yet.
• Guide treatment decisions, helping doctors adjust therapies based on how well the leukemia is responding to treatment.

Preparation
• No special preparation is required for this test.
• A blood sample is drawn from a vein in your arm, or a bone marrow sample may be used if the blood test is inconclusive.
• Timing of the test: It’s often performed at regular intervals (e.g., every 3–6 months) during treatment to assess response to therapy and to check for potential relapse.
• Inform your doctor about any medications or treatments you are currently undergoing, especially targeted therapies such as tyrosine kinase inhibitors.

Related products